EU approves skin cancer fighting drug: Roche

Swiss drug giant Roche said on Monday it had been given European Union approval for its treatment to fight a highly aggressive form of skin cancer.

The European Commission gave the green light to Zelboraf, a drug used to treat adults with BRAF V600 mutation-positive unresectable or , the company announced in a statement.

If diagnosed early is generally curable but when it spreads to other parts of the body it is the deadliest form of .

Currently only one in four people lives for more than a year following diagnosis.

US approved Zelboraf in August last year, with Roche describing initial sales as "very encouraging."

The group recorded Zelboraf sales worth 31 million Swiss francs (25.7 million euros) in 2011.

The treatment, already approved by Switzerland, Brazil and Canada among others, has "revolutionised melanoma treatment," said analysts at the Zurich Cantonal Bank (ZKB).

Roche said the drug allows people to live significantly longer, with trials showing the risk of death was reduced by 63 percent for people who received Zelboraf compared to those who received standard first-line treatment.

add to favorites email to friend print save as pdf

Related Stories

US approves new drug against skin cancer

Aug 17, 2011

A breakthrough drug that could extend survival in some patients with advanced skin cancer was approved on Wednesday by US regulators, offering the first new treatment for melanoma in 13 years.

US approves Swiss firm's cervical cancer test

Apr 20, 2011

Swiss pharmaceutical giant Roche has been given the green light by US authorities to market its test for screening cervical cancer, the company announced on Wednesday.

Recommended for you

Video: Is that double mastectomy really necessary?

24 minutes ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments